Abstract: FR-PO881
Impact of Proteinuria Level and CKD Stage on Health Care Resource Utilization among Adults with IgA Nephropathy in Spain
Session Information
- IgA Nephropathy: Clinical, Outcomes, and Therapeutics
October 25, 2024 | Location: Exhibit Hall, Convention Center
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics
Authors
- Schaufler, Thilo, CSL Vifor, Glattbrugg, Switzerland
- Ramirez de Arellano, Antonio, CSL Vifor, Glattbrugg, Switzerland
- Dasgupta, Sonali, IQVIA Inc, Wayne, Pennsylvania, United States
Background
Patients with immunoglobulin A nephropathy (IgAN) and proteinuria ≥1.0 g/day are at increased risk of disease progression. This study assessed the impact of chronic kidney disease (CKD) stage and proteinuria level on healthcare resource utilization (HRU) and costs among patients with IgAN in Spain.
Methods
Patients who were included had ≥1 ICD-9 583.9, ICD-10 N02.8, or ICD-10 N02.9 code recorded between 2015 and 2022. CKD stage was defined by ICD-10 N18 code and estimated glomerular filtration rate. Patients were divided into two subgroups based on proteinuria: <1 g/day and ≥1 g/day. Average HRU costs for in-patient, out-patient and emergency visits were calculated using Official Journal of the Catalan government prices for 2020 and published literature.
Results
1,080 patients with IgAN (mean age 53 years, 66% male) were identified. The mean total cost per patient with CKD stage 5 was >12-fold higher than for stage 1 (€56,858 vs €4,449). Mean total cost per patient was >2-fold higher with proteinuria ≥1 g/day than with <1 g/day (€5,236 vs €2,449) (Figure 1). Average number of visits per year increased with advancing CKD stage for all visit types, and with higher proteinuria level for out-patient and emergency visits (Figure 2).
Conclusion
In Spanish patients with IgAN, advanced CKD stage and elevated proteinuria were associated with higher HRU and costs across visit types. Interventions to lower proteinuria may help prevent rapid kidney function decline and reduce IgAN-related HRU and costs.
Funding
- Commercial Support – CSL Vifor